Preferred Label : Eliglustat;
NCIt synonyms : N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1-ylmethyl)ethyl)octanamide;
NCIt definition : A ceramide analog and an orally bioavailable inhibitor of glucosylceramide synthase
(GCS; ceramide glucosyltransferase), that may be used to decrease the production of
glycosphingolipids (GSLs) including glucosylceramide, also known as glucocerebroside.
Upon oral administration, eliglustat inhibits GCS, which catalyzes the initial step
in the synthesis of glucosylceramide and other GSLs. This decreases the production
of glucosylceramide and other GSLs, which have important roles in various diseases
and cellular processes, including immune processes and functions. Eliglustat may be
used in substrate reduction therapy in diseases in which the enzyme glucocerebrosidase
(GCase), responsible for the breakdown of glucocerebroside, is deficient.;
UNII : DR40J4WA67;
InChIKey : FJZZPCZKBUKGGU-AUSIDOKSSA-N;
CAS number : 491833-29-5;
Molecule name : GENZ 99067; GENZ-99067;
Chemical formula : C23H36N2O4;
Origin ID : C96282;
UMLS CUI : C3272698;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
